vs

Side-by-side financial comparison of Eastern Bankshares, Inc. (EBC) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Eastern Bankshares, Inc. is the larger business by last-quarter revenue ($295.9M vs $225.6M, roughly 1.3× Organogenesis Holdings Inc.). Eastern Bankshares, Inc. runs the higher net margin — 22.1% vs 19.4%, a 2.7% gap on every dollar of revenue. On growth, Eastern Bankshares, Inc. posted the faster year-over-year revenue change (710.6% vs 78.1%). Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs 38.6%).

Eastern Bank is a bank based in Boston, Massachusetts. Before de-mutualizing in 2020, it was the oldest and largest mutual bank in the United States and the largest community bank in Massachusetts.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

EBC vs ORGO — Head-to-Head

Bigger by revenue
EBC
EBC
1.3× larger
EBC
$295.9M
$225.6M
ORGO
Growing faster (revenue YoY)
EBC
EBC
+632.5% gap
EBC
710.6%
78.1%
ORGO
Higher net margin
EBC
EBC
2.7% more per $
EBC
22.1%
19.4%
ORGO
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
38.6%
EBC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
EBC
EBC
ORGO
ORGO
Revenue
$295.9M
$225.6M
Net Profit
$65.3M
$43.7M
Gross Margin
Operating Margin
28.1%
Net Margin
22.1%
19.4%
Revenue YoY
710.6%
78.1%
Net Profit YoY
-34.4%
469.5%
EPS (diluted)
$0.29
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EBC
EBC
ORGO
ORGO
Q1 26
$295.9M
Q4 25
$37.5M
$225.6M
Q3 25
$241.5M
$150.9M
Q2 25
$244.9M
$101.0M
Q1 25
$31.1M
$86.7M
Q4 24
$216.5M
$126.7M
Q3 24
$203.4M
$115.2M
Q2 24
$154.0M
$130.2M
Net Profit
EBC
EBC
ORGO
ORGO
Q1 26
$65.3M
Q4 25
$99.5M
$43.7M
Q3 25
$106.1M
$21.6M
Q2 25
$100.2M
$-9.4M
Q1 25
$-217.7M
$-18.8M
Q4 24
$60.8M
$7.7M
Q3 24
$-6.2M
$12.3M
Q2 24
$26.3M
$-17.0M
Gross Margin
EBC
EBC
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
EBC
EBC
ORGO
ORGO
Q1 26
Q4 25
28.1%
Q3 25
38.9%
13.7%
Q2 25
41.0%
-12.5%
Q1 25
-590.9%
-30.9%
Q4 24
33.3%
8.1%
Q3 24
-1.6%
5.4%
Q2 24
24.7%
-10.7%
Net Margin
EBC
EBC
ORGO
ORGO
Q1 26
22.1%
Q4 25
265.6%
19.4%
Q3 25
44.0%
14.3%
Q2 25
40.9%
-9.3%
Q1 25
-699.2%
-21.7%
Q4 24
28.1%
6.1%
Q3 24
-3.0%
10.7%
Q2 24
17.1%
-13.1%
EPS (diluted)
EBC
EBC
ORGO
ORGO
Q1 26
$0.29
Q4 25
$0.48
$0.31
Q3 25
$0.53
$0.11
Q2 25
$0.50
$-0.10
Q1 25
$-1.08
$-0.17
Q4 24
$0.29
$0.05
Q3 24
$-0.03
$0.09
Q2 24
$0.16
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EBC
EBC
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$551.7M
$93.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$4.3B
$300.1M
Total Assets
$30.6B
$598.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EBC
EBC
ORGO
ORGO
Q1 26
$551.7M
Q4 25
$507.6M
$93.7M
Q3 25
$703.4M
$63.7M
Q2 25
$948.3M
$73.1M
Q1 25
$609.0M
$110.0M
Q4 24
$1.9B
$135.6M
Q3 24
$1.7B
$94.3M
Q2 24
$1.4B
$89.9M
Total Debt
EBC
EBC
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
EBC
EBC
ORGO
ORGO
Q1 26
$4.3B
Q4 25
$4.3B
$300.1M
Q3 25
$3.8B
$255.1M
Q2 25
$3.7B
$233.2M
Q1 25
$3.6B
$242.9M
Q4 24
$3.6B
$262.9M
Q3 24
$3.7B
$278.5M
Q2 24
$3.0B
$263.5M
Total Assets
EBC
EBC
ORGO
ORGO
Q1 26
$30.6B
Q4 25
$30.6B
$598.7M
Q3 25
$25.5B
$509.8M
Q2 25
$25.5B
$461.1M
Q1 25
$25.0B
$467.4M
Q4 24
$25.6B
$497.9M
Q3 24
$25.5B
$446.3M
Q2 24
$21.0B
$443.2M
Debt / Equity
EBC
EBC
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EBC
EBC
ORGO
ORGO
Operating Cash FlowLast quarter
$39.4M
Free Cash FlowOCF − Capex
$34.8M
FCF MarginFCF / Revenue
15.4%
Capex IntensityCapex / Revenue
2.1%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EBC
EBC
ORGO
ORGO
Q1 26
Q4 25
$432.4M
$39.4M
Q3 25
$157.1M
$3.1M
Q2 25
$123.9M
$-32.9M
Q1 25
$47.3M
$-19.9M
Q4 24
$283.8M
$10.9M
Q3 24
$108.3M
$8.7M
Q2 24
$54.3M
$4.7M
Free Cash Flow
EBC
EBC
ORGO
ORGO
Q1 26
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
FCF Margin
EBC
EBC
ORGO
ORGO
Q1 26
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Capex Intensity
EBC
EBC
ORGO
ORGO
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Cash Conversion
EBC
EBC
ORGO
ORGO
Q1 26
Q4 25
4.35×
0.90×
Q3 25
1.48×
0.14×
Q2 25
1.24×
Q1 25
Q4 24
4.67×
1.43×
Q3 24
0.71×
Q2 24
2.06×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons